Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | January 13, 2025 |
| Target | Intra-Cellular Therapies |
| Sector | Life Science |
| Buyer(s) | Johnson & Johnson |
| Deal Type | Add-on Acquisition |
| Deal Value | 14.6B USD |
| Advisor(s) | Centerview Partners Jefferies (Financial) Davis Polk & Wardwell (Legal) |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1886 |
| Sector | Consumer Products |
| Employees | 132,000 |
| Revenue | 88.8B USD (2024) |
Johnson & Johnson is a global healthcare conglomerate that operates across three primary sectors: Pharmaceuticals, Medical Devices, and Consumer Health. In Pharmaceuticals, it develops treatments for a variety of conditions, including immunology, oncology, and infectious diseases. The Medical Devices segment offers a range of equipment and devices for healthcare professionals, encompassing orthopedics, surgery, and cardiovascular care. Its Consumer Health division markets a wide array of products, spanning baby care, oral care, skin care, over-the-counter drugs, and women's health, with popular brands such as Band-Aid, Tylenol, and Neutrogena under its umbrella. Johnson & Johnson was formed in 1886 and is based in New Brunswick, New Jersey.
| Deal Context for Buyer | # |
|---|---|
| Overall | 46 of 47 |
| Sector: Life Science | 19 of 20 |
| Type: Add-on Acquisition | 38 of 39 |
| State: New Jersey | 3 of 3 |
| Country: United States | 38 of 39 |
| Year: 2025 | 1 of 2 |
| Size (of disclosed) | 5 of 31 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-10-09 |
V-Wave
Caesarea, Israel V-Wave develops percutaneous implantable technologies for patients with chronic heart failure. V-Wave was formed in 2009 and is headquartered in Caesarea, Israel. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-11-17 |
Halda Therapeutics
New Haven, Connecticut, United States Halda Therapeutics is a clinical-stage biotechnology company developing a novel class of cancer therapies based on its proprietary RIPTAC (Regulated Induced Proximity Targeting Chimeras) platform. The RIPTAC modality works via a “hold-and-kill” mechanism, binding a tumor-specific protein and an essential cellular protein to trigger selective cancer-cell death. Halda Therapeutics is based in New Haven, Connecticut |
Buy | $3.1B |
